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We have read with keen interest a paper by Aksu et al. [1]. 
The problem addressed in this article is relevant, since aspirin 
is abundantly used in high risk patients to prevent cardio-
vascular (CV) disease; in addition many other anticoagulant 
and antiplatelet agents emerged recently and their clinical 
significance in CV diseases is a subject of ongoing discussion 
[2, 3]. Aksu et al. [1] have reported that the prevalence of 
aspirin resistance (AR) increases in chronic kidney disease 
(CKD) stages 4 and 5 (estimated glomerular filtration rate 
[eGFR] < 30 mL/min/1.73 m2, with 86% of patients on 
haemodialysis), as compared to the remaining 3 groups 
(i.e. eGFR > 90 [control], eGFR 60–90 [stage 2] and eGFR 
30–60 mL/min/1.73m2 [stage 3]). Interestingly, they observed 
that AR is weakly correlated to eGFR [1]. 
First, it is worth noting that according to recent data, 
sta ge 2 CKD (eGFR 60–90 mL/min/1.73 m2), especially in 
patients aged on average 62 years, is considered as an artificial 
category derived from imperfections of the GFR calculation 
and not as true pathology; the same applies also to many older 
patients with CKD stage 3. In this context there is no reason 
to expect any influence of kidney function on aspirin-induced 
platelet reactivity in CKD except from advanced renal failure 
as has been shown also by others [4]. 
A sharp increase in AR prevalence in CKD stage 4–5 may 
be related to profound metabolic disturbances of chronic 
uremia, although it is rather platelet dysfunction and uremic 
diathesis than increased risk of thrombosis that are more 
common in such patients [5]. Apart from multiple complex 
mechanisms of AR mentioned by Aksu et al. [1], a few other 
potential factors should be considered. Firstly, phosphate 
binders (calcium carbonate and citrate, lanthanum carbon-
ate, sevelamer and — occasionally — aluminum hydroxide), 
commonly used in patients on haemodialysis (HD) and very 
infrequently administered in earlier CKD stages, could sub-
stantially affect acetylsalicylic acid (ASA) bioavailability. This 
confounding factor has been not included in their analysis. We 
cannot exclude any interactions between ASA and phosphate 
binder use. Secondly, proton pump inhibitors (PPI) seem to be 
overused in dialysis population (more than 50% of subjects in 
some HD cohorts receive these drugs) and clinical data have 
suggested that PPI may attenuate antiplatelet effects of ASA [6]. 
The second important issue related to the work by Aksu 
et al. [1] is a benefit expected from the use of ASA in CKD. 
Indeed, post-hoc analysis of the HOT trial has shown that re-
duction in major CV events and hospitalisation associated with 
ASA use was inversely correlated with eGFR (with the highest 
benefit observed in patients with eGFR < 45 mL/min/1.73 m2). 
Bleeding complications were also increasing with loss of GFR, 
but did not offset CV benefits. There were however only 
536 patients (out of 18,597 in the HOT trial) with this level 
of eGFR (mean 40 mL/min./1.73 m2, interquartile range: 
32–43, and no patients with CKD stage 4–5) [7]. Despite 
lack of convincing data, ASA is frequently prescribed to HD 
patients; a recent large epidemiological study has showed that 
8% to 36% of HD patients (depending on a country) were 
using this drug [8]. Patients on HD have significantly higher 
risk of bleeding and aspirin use is associated with increased 
adjusted risk of mortality, or — at best — has no impact on 
outcome [8, 9]. We are convinced that there is no reason to 
expect any long-term benefit from the use of aspirin in patients 
with advanced CKD in terms of CV end-points and mortality; 
the advantage of ASA is probably limited to longer patency 
of vascular grafts used as an access for HD [10]. We believe 
that data showing benefits from the use of ASA in secondary 
prevention cannot be extrapolated from the general popula-
tion to subjects with advanced CKD. Although prevalence of 
AR is high in this patient group, it would probably have very 
little impact on patient prognosis. 
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